ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 094,97
-0,09%
Dow Jones
39 069,59
0,01%
DAX
18 693,37
0,04%
Brent Oil
81,965
0,00%
Bitcoin
69 087,06
-0,26%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Hepion Pharmaceuticals Inc (HEPA)

  7. Hepion Pharmaceuticals Inc (HEPA) Actualités

HEPA

Hepion Pharmaceuticals (HEPA)

Hepion Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:HEPA
DateHeureSourceTitreSymboleSociété
21/05/202423h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HEPAHepion Pharmaceuticals Inc
15/05/202422h46Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:HEPAHepion Pharmaceuticals Inc
19/04/202422h30GlobeNewswire Inc.Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialNASDAQ:HEPAHepion Pharmaceuticals Inc
16/02/202415h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HEPAHepion Pharmaceuticals Inc
16/02/202414h00GlobeNewswire Inc.Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsNASDAQ:HEPAHepion Pharmaceuticals Inc
14/02/202421h38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:HEPAHepion Pharmaceuticals Inc
03/01/202423h15GlobeNewswire Inc.Hepion Pharmaceuticals to Present at NASH-TAG 2024NASDAQ:HEPAHepion Pharmaceuticals Inc
07/12/202314h00GlobeNewswire Inc.Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesNASDAQ:HEPAHepion Pharmaceuticals Inc
28/11/202322h15GlobeNewswire Inc.Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitNASDAQ:HEPAHepion Pharmaceuticals Inc
13/11/202322h05GlobeNewswire Inc.Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseNASDAQ:HEPAHepion Pharmaceuticals Inc
10/11/202314h50GlobeNewswire Inc.Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
09/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:HEPAHepion Pharmaceuticals Inc
25/10/202314h30GlobeNewswire Inc.Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer ModelNASDAQ:HEPAHepion Pharmaceuticals Inc
29/09/202314h00GlobeNewswire Inc.Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq RulesNASDAQ:HEPAHepion Pharmaceuticals Inc
21/09/202322h05GlobeNewswire Inc.Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare ConferenceNASDAQ:HEPAHepion Pharmaceuticals Inc
21/09/202314h00GlobeNewswire Inc.New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening ProgramNASDAQ:HEPAHepion Pharmaceuticals Inc
19/09/202315h00GlobeNewswire Inc.Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver CancerNASDAQ:HEPAHepion Pharmaceuticals Inc
18/09/202314h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HEPAHepion Pharmaceuticals Inc
14/09/202314h45GlobeNewswire Inc.Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary FibrosisNASDAQ:HEPAHepion Pharmaceuticals Inc
06/09/202322h30GlobeNewswire Inc.Hepion Pharmaceuticals Announces Management ChangesNASDAQ:HEPAHepion Pharmaceuticals Inc
21/07/202322h39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HEPAHepion Pharmaceuticals Inc
15/06/202322h45GlobeNewswire Inc.Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023NASDAQ:HEPAHepion Pharmaceuticals Inc
15/06/202314h22GlobeNewswire Inc.Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
24/05/202322h45GlobeNewswire Inc.Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical SciencesNASDAQ:HEPAHepion Pharmaceuticals Inc
22/05/202313h00GlobeNewswire Inc.Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH BiomarkersNASDAQ:HEPAHepion Pharmaceuticals Inc
19/05/202322h05GlobeNewswire Inc.Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatNASDAQ:HEPAHepion Pharmaceuticals Inc
12/05/202322h19Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:HEPAHepion Pharmaceuticals Inc
10/05/202317h15GlobeNewswire Inc.Hepion Pharmaceuticals, Inc. Announces Reverse Stock SplitNASDAQ:HEPAHepion Pharmaceuticals Inc
17/04/202322h15GlobeNewswire Inc.Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023NASDAQ:HEPAHepion Pharmaceuticals Inc
10/04/202322h52Edgar (US Regulatory)Annual Report (10-k)NASDAQ:HEPAHepion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:HEPA

Dernières Valeurs Consultées

EU
SGO
Cie de SaintGobain
EU
RI
Pernod Ricard
NASDAQ
MSFT
Microsoft
NYSE
MRK
Merck
EU
AI
Air Liquide
EU
CAP
Capgemini
EU
GLE
Societe Generale
EU
BNP
BNP Paribas
NASDAQ
AMZN
Amazon.com
NASDAQ
AAPL
Apple
EU
DG
Vinci
EU
BN
Danone
EU
ACA
Credit Agricole
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés